natgillin/translations-raw huggingface dataset:
The use according to claim 5, wherein said genitourinary disease is: reduced bladder capacity; frequent micturition; urge incontinence; stress incontinence; bladder hyperreactivity; benign prostatic hypertrophy; prostatitis; detrusor hyperreflexia; urinary frequency; nocturia; urinary urgency; overactive bladder; pelvic hypersensitivity; urethritis; pelvic pain syndrome; prostatodynia; cystitis; or idiophatic bladder hypersensitivity; and the disease which is associated with pain is: inflammatory pain; surgical pain; visceral pain; dental pain; premenstrual pain; central pain; pain due to burns; migraine or cluster headaches; nerve injury; neuritis; neuralgias; poisoning; ischemic injury; interstitial cystitis; cancer pain; viral, parasitic or bacterial infection; post-traumatic injury; or pain associated with irritable bowel syndrome. 
Uporaba spoja prema zahtjevu 5, naznačena time, da spomenuta genitourinarna bolest je: smanjenje kapaciteta mjehura; učestalo mokrenje; ubrzana inkontinencija; inkontinencija s pritiskom; hiperreaktivnost mjehura; benigna prostatska hipertrofija; prostatitis; hiperrefleksija detruzora; urinarna frekvencija; učestalo noćno mokrenje; urinarna urgencija; prekomjerno aktivni mjehur; hipersenzibilnost karlice; uretritis; sindrom bolne karlice; prostatodinija; cistitis; ili idiopatska hipersenzibilnost mjehura; a bolest koja je povezana s bolovima je: upalna bol, kirurška bol; organska bol; zubobolja; predmenstrualna bol; središnja bol; bol kod opeklina; migrena ili serijske glavobolje; povreda živca; neuritis; neuralgije; otrovanje; ishemijska ozljeda; intersticijalni cistitis; bol kod tumora; viroza, infekcija parazitima ili bakterijama; post-traumatska ozljeda; ili bol povezana sa sindromom osjetljivih crijeva.
A compound according to claim 1 which is selected from the group consisting of: N2-Isopropyl-5-(2-isopropyl-4,5-dimethoxy-benzyl)-N4-methyl-pyrimidine-2,4-diamine, 
Spoj formule I prema zahtjevu 1, naznačen time, da je odabran iz skupine koju čine: -(2-izopropil-4,5-dimetoksi-fenoksi)-pirimidin-2,4-diamin;
The pharmaceutical composition of claim 1, wherein the stability is at least 5-80% greater, under pre-selected conditions, than the stability of a composition which differs by lacking the carbohydrate, and wherein the carbohydrate is present in an amount sufficient to inhibit the reaction of a free thiol on a first molecule of the protein with a free thiol on a second molecule of the protein to form an aggregate, wherein preferably the carbohydrate is present in an amount sufficient to inhibit the formation of an aggregate by at least 5-80 %, under pre-selected conditions, as compared to the same composition lacking the carbohydrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za inhibiranje reakcije slobodnog tiola na prvoj molekuli proteina sa slobodnim tiolom na drugoj molekuli proteina kojom se formira agregat. Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za inhibiranje formiranja agregata koji se formira reakcijom slobodnog tiola na prvoj molekuli proteina sa slobodnim tiolom na drugoj molekuli proteina za najmanje od 5-80 %, pod unaprijed izabranim uvjetima, u usporedbi sa istom kompozicijom koja ne sadrži ugljikohidrat.
The pharmaceutical composition of claim 1, wherein the carbohydrate is present in an amount sufficient that upon storage, in a gas tight container, at a temperature of 2-8°C, for a period of 6 months, the composition will retain at least 85% of the stability the composition had prior to storage, wherein preferably the storage occurs in darkness. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da poslije čuvanja u kontejneru nepropusnom za plin, na temperaturi od 2-, u razdoblju od 6 mjeseci, kompozicija zadrži najmanje 85% stabilnosti koju je kompozicija imala prije čuvanja.
The pharmaceutical composition of claim 1, wherein the carbohydrate is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising sucrose, 0.01 % polysorbate-20, pH 6.0, 50 mM Citrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da ona ima stabilnost koja odgovara onoj za liofiliziranu kompoziciju koja sadrži saharozu, 0,01 % polisorbata-20, pH 6,0, citrata.
preparing a semimanufactured component of an upper (12) for a shoe, such that it can be arranged spread out on a flat surface, 
priprave poluproizvedenog dijela gornjišta (12) za cipelu koje se može rasprostrijeti na ravnoj površini ili na dvije suprotne površine
performing a curd and whey separation, wherein a cheese alternative product is obtained, which contains ≥ 5 (w/w) % fat, preferably 5 to 30 (w/w) % fat, more preferably 5 to 25 (w/w) % fat and most preferably 5 to 20 (w/w) % fat. 
razdvajanje skute i sirutke, čime se dobiva zamjenski sirni proizvod koji sadrži > 5 (w/w) % masti, poželjno je 5 do 30 (w/w) % masti, poželjnije je 5 do 25 (w/w) % masti, a najpoželjnije je 5 do 20 (w/w) % masti.
The method of any of claims 1 to 5, wherein the mixture in step d) comprises edible oil at a concentration of 4 to 17 (w/w) %, preferably 8 to 17 (w/w) %, more preferably 9 to 17 (w/w) %. 
Postupak iz bilo kojeg patentnog zahtjeva 1 do 5, naznačen time, da smjesa u fazi d) sadrži jestivo ulje koncentracije 4 do 17 (w/w) %, poželjno je 8 do 17 (w/w) %, poželjnije je 9 do 17 (w/w) %.
A pharmaceutical composition comprising a protein having a free thiol and a carbohydrate, wherein the carbohydrate is resent in an amount sufficient to maintain the stability of the protein and wherein the pH of the composition is between 4.5 and 6.5, wherein the protein having a free thiol is glucocerebrosidase (GCB), and wherein the carbohydrate is sucrose. 
Farmaceutska kompozicija koja sadrži protein koji ima slobodni tiol i ugljikohidrat, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za održavanje stabilnosti proteina i pri čemu je pH kompozicije između 4,5 i 6,5, pri čemu je protein koji ima slobodni tiol glukocerebrozidaza (GCB) i pri čemu je ugljikohidrat saharoza.
The pharmaceutical composition of claim 1, wherein the stability is at least 5-80 % greater, under pre-selected conditions, than the stability of a composition which differs by lacking the carbohydrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu joj je stabilnost najmanje od 5-80 % veća, pod unaprijed izabranim uvjetima, od stabilnosti kompozicije koja se razlikuje po tome što ne sadrži ugljikohidrat.
The pharmaceutical composition of claim 1, wherein the carbohydrate, is present in an amount sufficient to increase the stability of the protein. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za povećanje stabilnosti proteina.
The pharmaceutical composition of claim 1, wherein the carbohydrate is present in an amount sufficient to inhibit the reaction of a free thiol on a first molecule of the protein with a free thiol on a second molecule of the protein to form an aggregate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za inhibiranje reakcije slobodnog tiola na prvoj molekuli proteina sa slobodnim tiolom na drugoj molekuli proteina kojom se formira agregat.
The pharmaceutical composition of claim 1, wherein the carbohydrate is present in an amount sufficient to inhibit the formation of an aggregate formed by the reaction of a free thiol on a first molecule of the protein with a free thiol on a second molecule of the protein by at least 5-80 %, under pre-selected conditions, as compared to the same composition lacking the carbohydrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za inhibiranje formiranja agregata koji se formira reakcijom slobodnog tiola na prvoj molekuli proteina sa slobodnim tiolom na drugoj molekuli proteina za najmanje od 5-80 %, pod unaprijed izabranim uvjetima, u usporedbi sa istom kompozicijom koja ne sadrži ugljikohidrat.
The pharmaceutical composition of claim 1 wherein the carbohydrate is present in an amount sufficient that upon storage, in a gas tight container, at a temperature of 2-8°C, for a period of 6 months, the composition will retain at least 85% of the stability the composition had prior to storage. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da poslije čuvanja u kontejneru nepropusnom za plin, na temperaturi od 2-, u razdoblju od 6 mjeseci, kompozicija zadrži najmanje 85% stabilnosti koju je kompozicija imala prije čuvanja.
The pharmaceutical composition of claim 24, comprising about 0.1-40 mg/ml GCB, about 0.001-10% cysteine, 1-40 % sucrose, at a pH of 5.5-6.0, and wherein the level of dissolved O2 is less than about 10 %. 
Farmaceutska kompozicija prema zahtjevu 24, pri čemu kompozicija sadrži 0,1-40 mg/ml GCB, 0,001-10 % cisteina, 1-40 % saharoze, pH 5,5-6,0, i pri čemu je nivo otopljenog O2 manji od oko 10 %.
The method of claim 31, wherein the inert gas is N2 or Ar and the reactive species is O2. 
Postupak prema zahtjevu 31, pri čemu je inertni plin N2 ili Ar i reaktivna vrsta je O2.
a drive wheel (9) the rotation axle of which is parallel to that of said drum (2); 
pogonskog kotača (9) čija je os rotacije paralelna sa onom od navedenog bubnja (2);
The device as claimed in claim 3 or 4, comprising means of continuously inserting the longitudinal edges of the cover into each of the rails (6) as it is gradually unwound from the drum (2), so that said edges are jammed reversibly in the rails through the action of the belts (31). 
Uređaj prema zahtjevu 3 ili 4, naznačen time da sadrži sredstva za neprekidno umetanje uzdužnih rubova pokrova u svaku šinu (6) dok se postupno odmata sa bubnja (2), tako da su navedeni rubovi reverzibilno zaglavljeni u šinama pomoću djelovanja remenja (31).
The device as claimed in claim 9, in which said modifying means comprise means of transmitting the rotational movement of the drive wheels (9) to the drum (2) by applying a friction force such that the rotation of the drum and of the drive wheels is in phase when the resistance to rotation of the drum afforded by the cover as it is being wound on to the drum is below a given value and is differentiated when the resistance exceeds said value, the rotational speed of the drum then being lower than that of the drive wheels. 
Uređaj prema zahtjevu 9, naznačen time da navedena sredstva za mijenjanje sadrže sredstva za prijenos rotacijskog kretanja pogonskih kotača (9) na bubanj (2) pomoću primjene sile trenja tako da je rotacija bubnja i pogonskih kotača u fazi kada je otpor rotaciji bubnja koju pruža pokrov dok se namotava na bubanj ispod zadane vrijednosti, te se razlikuje kada otpor premaši navedenu vrijednost, te je brzina rotacije bubnja tada niža nego brzina rotacije pogonskih kotača.
The device as claimed in claim 10, in which said friction force is applied to the drum via a belt or by circumferential contact by two rotating rollers. 
Uređaj prema zahtjevu 10, naznačen time da se navedena sila trenja primjenjuje na bubanj preko remena ili preko obodnog kontakta dva rotirajuća valjka.
The device as claimed in any one of claims 1 to 11 in which the rotation axle of the drum is distinct from that of the pinions or sprockets. 
Uređaj prema bilo kojem od zahtjeva 1 do 11 naznačen time da je os rotacije bubnja udaljena od osi rotacije malih zupčanika ili lančanika.
The device as claimed in any one of claims 3 to 13, in which the casters (33) engage in the rails and are mounted on the carriage (21) in such a way that they are free to move transversely over a certain distance along their axle in order to compensate for deviations in the parallelism of the rails (6). 
Uređaj prema bilo kojem od zahtjeva 3 do 13, naznačen time da su kotačići (33) u zahvatu sa šinama, te su postavljeni na klizač (21) na takav način da im je omogućeno slobodno poprečno pomicanje preko određene udaljenosti uzduž njihove osovine kako bi se mogla kompenzirati odstupanja paralelnosti šina (6).
Each Ra is independently selected from the group consisting of -C1-C4 alkyl, -C2-C4 alkenyl, cyclopropyl, -OC1-C2alkyl, -C(=O)C 1-C2alkyl, -C(=O)H, -CO2C1-C4alkyl, -OH, -NR3R4, - NR3C(=O)OC1-C4 alkyl, -S(O)xC1-C2 alkyl, halogen, -CN, -NO2, and a 5-6-membered heterocyclic ring having 1-2 heteroatoms independently selected from N, S, and O, wherein the point of attachment of said heterocyclic ring to the ring to which Ra is attached is a carbon atom, wherein said heterocyclic ring is optionally substituted with 1-5 substituent groups independently selected from halogen; 
svako Ra je nezavisno izabrano iz grupe koju čine -C1-C4 alkil, -C2-C4 alkenil, ciklopropil, -OC1-C2alkil, -C(=O)C1-C2alkil, -C(=O)H, -CO2C1-C4alkil, -OH, -NR3R4, - NR3C(=O)OC1-C4 alkil, -S(O)xC1-C2 alkil, halogen, -CN, -NO2 i 5-6-člani heterociklični prsten koji ima 1-2 heteroatoma nezavisno izabrana od N, S i O, gdje je točka vezivanja navedenog heterocikličnog prstena za prsten za koji je Ra veezan – atom ugljika, pri čemu je navedeni heterociklični prsten izborno supstituiran sa 1-5 supstituišuće grupe nezavisno izabrane od halogena;
The compound of Claim 1, which is selected from the group consisting of compounds having Formula Ia, Ib, and Id, or a pharmaceutically acceptable salt thereof: and 
Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz grupe koju čine spojevi koji imaju formulu Ia, Ib i Id, ili njegova farmaceutski prihvatljiva sol: [image] [image] i [image]
The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein A2 and A3 are both phenyl; and Ra is selected from the group consisting of -C1-C4 alkyl which is optionally substituted with 1-5 fluorine atoms and is optionally also substituted with one group selected from -OH and -OCH3; -OC1-C2alkyl, which is optionally substituted with 1-3 fluorine atoms; -C2-C4 alkenyl; -C1-C2 alkyl which is substituted with one group -NR3R4; cyclopropyl; -C(=O)H; -OH; -NR3R4; -S(O)xC1-C2 alkyl; halogen; -CN; and -NO2. 
Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što su i A2 i A3 - fenil; i Ra je izabran iz grupe koju čine -C1-C4 alkil koji je izborno susptituiran sa 1-5 atoma fluora i izborno je takođe supstituiran sa jednom grupom koja je izabrana od -OH i -OCH3; -OC1-C2alkil, koji je izborno supstituiran sa 1-3 atoma fluora; -C2-C4 alkenil; -C1-C2 alkil koji je supstituiran sa jednom grupom -NR3R4; ciklopropil; -C(=O)H; -OH; -NR3R4; -S(O)xC1-C2 alkil; halogen; -CN; i -NO2.
The compound of Claim 1, which is selected from the group consisting of compounds with the formula (a) to (c), or a pharmaceutically acceptable salt thereof: 
Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz grupe koju čine spojevi sa formulom (a) do (c), ili njegova farmaceutski prihvatljiva sol:
The compound of Claim 1, selected from the group consisting of compounds having the formula (a) to (k), or a pharmaceutically acceptable salt thereof: 
Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz grupe koju čine spojevi koji imaju formulu (a) do (k), ili njegova farmaceutski prihvatljiva sol:
CEREAL AND FRUIT OIL 
ULJE ŽITARICA I VOĆNO ULJE
PROCESS FOR ENANTIOSELECTIVE SYNTHESIS OF SINGLE ENANTIOMERS OF THIO-SUBSTITUTED ARYLMETHANESULFINYL DERIVATIVES BY ASYMMETRIC OXIDATION 
POSTUPAK ZA ENANTIOSELEKTIVNU SINTEZU JEDNOSTRUKIH ENANTIOMERA DERIVATA TIO-SUPSTITUIRANOG ARILMETANSULFINILA POMOĆU ASIMETRIÄŚNE OKSIDACIJE
APTAMER AGAINST MIDKINE AND USE THEREOF 
APTAMER PROTIV MIDKINA I NJEGOVA UPORABA
Improvement of protein production 
POBOLJŠANJE PROIZVODNJE PROTEINA
Electronic apparatus, intelligent network and intelligent network implemented data processing method 
ELEKTRONIČKI UREĐAJ, INTELIGENTNA MREŽA I METODA ZA OBRADU PODATAKA PRIMIJENJENA NA INTELIGENTNU MREŽU
PROCESSES FOR PREPARING A SUBSTITUTED GAMMA-AMINO ACID 
POSTUPCI ZA PRIPREMANJE SUPSTITUIRANE GAMA-AMINOKISELINE
Synergistic mixtures for controlling invertebrate pests containing an anthanilamide compound and abamectin 
SINERGISTIÄŚKE SMJESE ZA KONTROLU ŠTETNIKA BESKRALJEŽNJAKA KOJE SADRŽE ANTANILAMIDNU TVAR I ABAMEKTIN
Synergistic mixtures for controlling invertebrate pests containing an anthranilamide compound and pyridalyl 
SINERGISTIÄŚKE SMJESE ZA KONTROLU ŠTETNIKA BESKRALJEŽNJAKA KOJE SADRŽE ANTANILAMIDNU TVAR I ABAMEKTIN
Synergistic mixtures for controlling invertebrate pests containing an anthranilamide compound and flonicamid 
SINERGISTIÄŚKE SMJESE ZA KONTROLU ŠTETNIKA BESKRALJEŽNJAKA KOJE SADRŽE ANTANILAMIDNU TVAR I ABAMEKTIN
-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds 
SPOJEVI 4-[2-(2 FLUOROFENOKSIMETIL)FENIL]PIPERIDINA
CAPSULE, SYSTEM AND METHOD FOR THE PREPARATION OF A BEVERAGE AND A METHOD FOR MANUFACTURING SUCH A CAPSULE 
KAPSULA, SUSTAV I POSTUPAK ZA PRIPREMU PIĆA I POSTUPAK PROIZVODNJE TAKVE KAPSULE
Substituted diazepan compounds as orexin receptor antagonists 
SUPSTITUIRANI SPOJEVI DIAZEPANA KAO ANTAGONISTI OREKSIN RECEPTORA
Atomiser comprising a counter and an end of operation lock 
RASPRŠIVAČ KOJI OBUHVAĆA BROJAČ I UREĐAJ ZA BLOKIRANJE
PEPTIDES THAT BIND TO THE ERYTHROPOIETIN RECEPTOR 
PEPTIDI KOJI SE VEŽU ZA RECEPTOR ERITROPOETINA
TREATMENT OF COGNITIVE DISORDERS WITH (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF 
LIJEÄŚENJE KOGNITIVNIH POREMEĆAJA POMOĆU (R)-7-KLORO-N-(KINUKLIDIN-3-IL)BENZO[B]TIOFEN-2-KARBOKSAMIDA I NJEGOVIH FARMACEUTSKI PRIHVATLJIVIH SOLI
POLYETHYLENE FOR THE PRODUCTION OF INTERMEDIATE BULK CONTAINERS 
POLIETILEN ZA PROIZVODNJU SPREMNIKA ZA RASUTE MEĐUPRODUKTE
Nicorandil carriers with enhanced stability 
NIKORANDIL NOSAÄŚI POVEĆANE STABILNOSTI
Cyclopropyl polymerase inhibitors 
INHIBITORI CIKLOPROPIL POLIMERAZE
Activin-ActRII Antagonists for use in treating anemia 
AKTIVIN-ACTRII ANTAGONISTI I UPORABE ZA LIJEÄŚENJE ANEMIJE
SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING ANTI- INFLAMMATORY ACTIVITY 
SPECIFIÄŚNI GLUKOKORTIKOSTEROIDNI SPOJ S PROTUUPALNIM DJELOVANJEM
RILUZOLE AQUEOUS SUSPENSIONS 
VODENE SUSPENZIJE RILUZOLA
' -substituted carba-nucleoside analogs for antiviral treatment 
KARBA-NUKLEOZIDNI ANALOZI ZA ANTIVIRUSNU TERAPIJU
APPARATUS AND METHOD FOR FILTERING LIQUIDS, PARTICULARLY ORGANIC LIQUIDS 
UREĐAJ I POSTUPAK ZA FILTRIRANJE TEKUĆINA, NAROČITO ORGANSKIH TEKUĆINA
ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS 
DERIVATI IZOKINOLINA KAO NK3 ANTAGONISTI
Medicaments for the treatment or prevention of fibrotic diseases 
DERIVATI INDOLINONA ZA LIJEÄŚENJE ILI PREVENCIJU FIBROZNIH BOLESTI
Arranging interaction and back pressure chambers for microfluidization 
METODA KOMORE ZA INTERAKCIJU I KOMORE POVRATNOG PRITISKA ZA MIKROFLUIDIZACIJU
SALMONELLA VACCINE IN POULTRY 
CJEPIVO PROTIV SALMONELE ZA PERAD
Capsule, device, and method for preparing infused beverages 
KAPSULA, UREĐAJ I POSTUPAK PRIPREME NAPITKA INFUZIJOM
TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST 
LIJEÄŚENJE PROGRESIVNE NEURODEGENERATIVNE BOLESTI IBUDILASTOM
METHODS OF TREATMENT OF ENDOBRONCHIAL INFECTIONS 
FORMULACIJE TOBRAMICINA ZA LIJEÄŚENJE ENDOBRONHIJALNIH INFEKCIJA
IMPROVED TESTOSTERONE GEL AND METHOD OF USE 
POBOLJŠANI TESTOSTERON U GELU I NAÄŚIN PRIMJENE
Formulations of 14-epi-analogues of vitamin D 
FORMULACIJE 14-EPI-ANALOGA VITAMINA D
Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication 
MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
METHOD FOR THE PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM 
POSTUPAK DOBIVANJA MONTELUKASTOVE KISELINE U IONSKOM TEKUĆEM MEDIJU
PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATING AGENTS 
DERIVATI PIRIDIN-4-ILA KAO SREDSTVA IMUNOMODULACIJE
PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS 
DERIVATI PIRIMIDINA ZA LIJEÄŚENJE ASTME, KOPB, ALERGIJSKOG RINITISA, ALERGIJSKOG KONJUKTIVITISA, ATOPIJSKOG DERMATITISA, KARCINOMA, HEPATITISA B, HEPATITISA C, HIV, HPV, BAKTERIJSKIH INFEKCIJA I DERMATOZE
USE OF PASIREOTIDE FOR THE TREATMENT OF ENDOGENOUS HYPERINSULINEMIC HYPOGLYCEMIA 
UPORABA PASIREOTIDA ZA LIJEÄŚENJE ENDOGENE HIPERINZULINEMIJSKE HIPOGLIKEMIJE
CASPOFUNGIN FORMULATIONS 
FORMULACIJE KASPOFUNGINA
COMPOUNDS USEFUL FOR INHIBITING CHK1 
SPOJEVI KORISNI ZA INHIBIRANJE CHK1
Loading-bridge construction for nautical use 
KONSTRUKCIJA MOSTA ZA UKRCAJ ZA NAUTIÄŚKU UPORABU
PHARMACEUTICAL COMPOSITION COMPRISING ALEGLITAZAR 
FARMACEUTSKI SASTAV KOJI SADRŽI ALEGLITAZAR
PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS 
DERIVATI PIRAZOLO PIRIDINA KAO INHIBITORI NADPH OKSIDAZE
A MEDICINAL FUSIDIC ACID CREAM MADE USING SODIUM FUSIDATE AND INCORPORATING A BIOPOLYMER AND A PROCESS TO MAKE IT 
MEDICINSKA KREMA S FUSIDINSKOM KISELINOM PROIZVEDENA KORIŠTENJEM NATRIJEVOG FUSIDATA I KOJA SADRŽI BIOPOLIMER, TE POSTUPAK ZA NJENU PROIZVODNJU
FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS 
FUZIONIRANI HETEROCIKLIÄŚKI SPOJEVI KORISNI KAO MODULATORI KINAZE
RENIN INHIBITORS 
INHIBITORI RENINA
A FAR-INFRARED ANION COMPOUND SANITARY NAPKIN AND PAD 
HIGIJENSKI ULOŽAK I JASTUÄŚIÄ† DALEKOG INFRACRVENOG ANIONSKOG SPOJA
High affinity antibodies to human IL-6 receptor 
ANTITIJELA S VISOKIM AFINITETOM ZA RECEPTOR HUMANOG IL 6
MACHINE FOR THE PREPARATION OF BEVERAGES BY INFUSION USING CARTRIDGES 
UREĐAJ ZA PRIPREMU PIĆA INFUZIJOM UZ UPORABU PATRONA
Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same 
MONOKLONALNA PROTUTIJELA KOJA SE VEŽU NA HGM-CSF I MEDICINSKI SASTAVI KOJI IH SADRŽE
Container for packaging and displaying products and method for forming it 
SPREMNIK ZA PAKIRANJE I IZLAGANJE PROIZVODA TE POSTUPAK ZA NJEGOVO OBLIKOVANJE
NEEDLE-FREE ADMINISTRATION OF FeLV VACCINES 
PRIMJENA CJEPIVA BEZ IGLE ZA FELV
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 
DERIVATI HIDROBENZAMIDA KAO INHIBITORI HSP90
SUSPENSION FORMULATIONS OF INSULINOTROPIC PEPTIDES AND USES THEREOF 
SUSPENZIJSKE FORMULACIJE INZULINOTROPNIH PEPTIDA I NJIHOVE UPORABE
PHARMACEUTICAL COMPOSITION OF A SODIUM CHANNEL BLOCKER AND A SELECTIVE SEROTONIN UPTAKE INHIBITOR 
FARMACEUTSKI SASTAVI NATRIJEVOG BLOKATORA KANALA I SELEKTIVNOG INHIBITORA UNOSA SEROTONINA
QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS 
DERIVATI KINOLINA KAO INHIBITORI KINAZE PI3
Apparatus and method for transmitting and receiving a broadcast signal 
UREĐAJ I METODA ZA PRIJENOS I PRIMANJE EMITIRANOG SIGNALA
Process for the Preparation of Compounds useful as inhibitors of SGLT 
POSTUPAK ZA PRIPRAVU SPOJEVA KOJI SU KORISNI KAO INHIBITORI SGLT-a
STORAGE BOX 
KUTIJA ZA POHRANU
NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES 
NOVI SPOJEVI KORISNI ZA LIJEÄŚENJE DEGENERATIVNIH I UPALNIH BOLESTI
NOVEL PYRAZOLE-4-N-ALKOXYCARBOXAMIDES AS MICROBIOCIDES 
NOVI PIRAZOL-4-N-ALKOKSIKARBOKSAMIDI KAO MIKROBIOCIDI
CRYSTAL OF 1,2-DIHYDROPYRIDINE COMPOUND AND METHOD FOR PRODUCING SAME 
KRISTAL 1,2-DIHIDROPIRIDINSKOG SPOJA I POSTUPAK ZA NJEGOVU PROIZVODNJU
HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES 
DERIVATI HETEROARIL PIROLIDINILA I PIPERIDINIL KETONA
DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST 
DIHIDROGENFOSFATNA SOL ANTAGONISTA RECEPTORA PROSTAGLANDINA D2
Catheter including composite guide and methods for use and manufacturing of the same 
KATETER KOJI SADRŽI KOMPOZITNU VODILICU I POSTUPCI ZA UPORABU I NJEGOVU PROIZVODNJU
Compounds useful for the treatment of degenerative and inflammatory diseases 
NOVI SPOJEVI KORISNI ZA LIJEÄŚENJE DEGENERATIVNIH I UPALNIH BOLESTI
MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER 
MONOKLONALNA ANTITIJELA PROTIV KLAUDINA-18 ZA LIJEÄŚENJE KANCERA
CONFORMATIONALLY RESTRICTED BIPHENYL DERIVATIVES FOR USE AS HEPATITIS C VIRUS INHIBITORS 
DERIVATI BIFENILA OGRANIÄŚENE KONFORMACIJE ZA UPORABU KAO INHIBITORI VIRUSA HEPATITISA C
RAILROAD WHEEL WITH WEAR RESISTANT FLANGE 
ŽELJEZNIÄŚKI KOTAÄŚ S VIJENCEM OTPORNIM NA TROŠENJE
Pharmaceutical dosage forms 
FARMACEUTSKI OBLICI DOZIRANJA